New Drug Modeling Solution - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512251251

Publication Date:

December 10, 2024

Pages:

108

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for New Drug Modeling Solution was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for New Drug Modeling Solution was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for New Drug Modeling Solution was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for New Drug Modeling Solution was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of New Drug Modeling Solution include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for New Drug Modeling Solution, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of New Drug Modeling Solution by region & country, by Type, and by Application.
The New Drug Modeling Solution market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding New Drug Modeling Solution.
麻豆原创 Segmentation
By Company
JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
lnstem(Leadscope)
Segment by Type:
Database
Software
Others
Segment by Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modeling
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of New Drug Modeling Solution manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of New Drug Modeling Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of New Drug Modeling Solution in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 New Drug Modeling Solution Product Introduction
1.2 Global New Drug Modeling Solution 麻豆原创 Size Forecast
1.3 New Drug Modeling Solution 麻豆原创 Trends & Drivers
1.3.1 New Drug Modeling Solution Industry Trends
1.3.2 New Drug Modeling Solution 麻豆原创 Drivers & Opportunity
1.3.3 New Drug Modeling Solution 麻豆原创 Challenges
1.3.4 New Drug Modeling Solution 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global New Drug Modeling Solution Players Revenue Ranking (2023)
2.2 Global New Drug Modeling Solution Revenue by Company (2019-2024)
2.3 Key Companies New Drug Modeling Solution Manufacturing Base Distribution and Headquarters
2.4 Key Companies New Drug Modeling Solution Product Offered
2.5 Key Companies Time to Begin Mass Production of New Drug Modeling Solution
2.6 New Drug Modeling Solution 麻豆原创 Competitive Analysis
2.6.1 New Drug Modeling Solution 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by New Drug Modeling Solution Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Drug Modeling Solution as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Database
3.1.2 Software
3.1.3 Others
3.2 Global New Drug Modeling Solution Sales Value by Type
3.2.1 Global New Drug Modeling Solution Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global New Drug Modeling Solution Sales Value, by Type (2019-2030)
3.2.3 Global New Drug Modeling Solution Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Drug Discovery and Development
4.1.2 Computational Physiological Medicine
4.1.3 Disease Modeling
4.1.4 Others
4.2 Global New Drug Modeling Solution Sales Value by Application
4.2.1 Global New Drug Modeling Solution Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global New Drug Modeling Solution Sales Value, by Application (2019-2030)
4.2.3 Global New Drug Modeling Solution Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global New Drug Modeling Solution Sales Value by Region
5.1.1 Global New Drug Modeling Solution Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global New Drug Modeling Solution Sales Value by Region (2019-2024)
5.1.3 Global New Drug Modeling Solution Sales Value by Region (2025-2030)
5.1.4 Global New Drug Modeling Solution Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America New Drug Modeling Solution Sales Value, 2019-2030
5.2.2 North America New Drug Modeling Solution Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe New Drug Modeling Solution Sales Value, 2019-2030
5.3.2 Europe New Drug Modeling Solution Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific New Drug Modeling Solution Sales Value, 2019-2030
5.4.2 Asia Pacific New Drug Modeling Solution Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America New Drug Modeling Solution Sales Value, 2019-2030
5.5.2 South America New Drug Modeling Solution Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa New Drug Modeling Solution Sales Value, 2019-2030
5.6.2 Middle East & Africa New Drug Modeling Solution Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions New Drug Modeling Solution Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions New Drug Modeling Solution Sales Value
6.3 United States
6.3.1 United States New Drug Modeling Solution Sales Value, 2019-2030
6.3.2 United States New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.3.3 United States New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe New Drug Modeling Solution Sales Value, 2019-2030
6.4.2 Europe New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China New Drug Modeling Solution Sales Value, 2019-2030
6.5.2 China New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.5.3 China New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan New Drug Modeling Solution Sales Value, 2019-2030
6.6.2 Japan New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea New Drug Modeling Solution Sales Value, 2019-2030
6.7.2 South Korea New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia New Drug Modeling Solution Sales Value, 2019-2030
6.8.2 Southeast Asia New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India New Drug Modeling Solution Sales Value, 2019-2030
6.9.2 India New Drug Modeling Solution Sales Value by Type (%), 2023 VS 2030
6.9.3 India New Drug Modeling Solution Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 JSR Corporation(Crown Bioscience)
7.1.1 JSR Corporation(Crown Bioscience) Profile
7.1.2 JSR Corporation(Crown Bioscience) Main Business
7.1.3 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Products, Services and Solutions
7.1.4 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.1.5 JSR Corporation(Crown Bioscience) Recent Developments
7.2 Chemical Computing Group ULC
7.2.1 Chemical Computing Group ULC Profile
7.2.2 Chemical Computing Group ULC Main Business
7.2.3 Chemical Computing Group ULC New Drug Modeling Solution Products, Services and Solutions
7.2.4 Chemical Computing Group ULC New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.2.5 Chemical Computing Group ULC Recent Developments
7.3 Nimbus Therapeutics
7.3.1 Nimbus Therapeutics Profile
7.3.2 Nimbus Therapeutics Main Business
7.3.3 Nimbus Therapeutics New Drug Modeling Solution Products, Services and Solutions
7.3.4 Nimbus Therapeutics New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.3.5 schrodinger, Inc Recent Developments
7.4 schrodinger, Inc
7.4.1 schrodinger, Inc Profile
7.4.2 schrodinger, Inc Main Business
7.4.3 schrodinger, Inc New Drug Modeling Solution Products, Services and Solutions
7.4.4 schrodinger, Inc New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.4.5 schrodinger, Inc Recent Developments
7.5 Genedata AG
7.5.1 Genedata AG Profile
7.5.2 Genedata AG Main Business
7.5.3 Genedata AG New Drug Modeling Solution Products, Services and Solutions
7.5.4 Genedata AG New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.5.5 Genedata AG Recent Developments
7.6 Biognos AB
7.6.1 Biognos AB Profile
7.6.2 Biognos AB Main Business
7.6.3 Biognos AB New Drug Modeling Solution Products, Services and Solutions
7.6.4 Biognos AB New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.6.5 Biognos AB Recent Developments
7.7 Compugen Ltd
7.7.1 Compugen Ltd Profile
7.7.2 Compugen Ltd Main Business
7.7.3 Compugen Ltd New Drug Modeling Solution Products, Services and Solutions
7.7.4 Compugen Ltd New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.7.5 Compugen Ltd Recent Developments
7.8 Dassault Systemes
7.8.1 Dassault Systemes Profile
7.8.2 Dassault Systemes Main Business
7.8.3 Dassault Systemes New Drug Modeling Solution Products, Services and Solutions
7.8.4 Dassault Systemes New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.8.5 Dassault Systemes Recent Developments
7.9 Acellera
7.9.1 Acellera Profile
7.9.2 Acellera Main Business
7.9.3 Acellera New Drug Modeling Solution Products, Services and Solutions
7.9.4 Acellera New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.9.5 Acellera Recent Developments
7.10 lnstem(Leadscope)
7.10.1 lnstem(Leadscope) Profile
7.10.2 lnstem(Leadscope) Main Business
7.10.3 lnstem(Leadscope) New Drug Modeling Solution Products, Services and Solutions
7.10.4 lnstem(Leadscope) New Drug Modeling Solution Revenue (US$ Million) & (2019-2024)
7.10.5 lnstem(Leadscope) Recent Developments
8 Industry Chain Analysis
8.1 New Drug Modeling Solution Industrial Chain
8.2 New Drug Modeling Solution Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 New Drug Modeling Solution Sales Model
8.5.2 Sales Channel
8.5.3 New Drug Modeling Solution Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
lnstem(Leadscope)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.